Download PDF
Dtsch Med Wochenschr 2019; 144(08): 553-560
DOI: 10.1055/a-0655-6454
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Enterokokken mit speziellen Resistenzen – Epidemiologie, Hygiene und Therapie

Enterococci With Special Resistance Patterns – Epidemiology, Hygiene and Therapy
Alexander Mischnik
,
Guido Werner
,
Jennifer Bender
,
Nico Tom Mutters
Further Information

Publication History

Publication Date:
15 April 2019 (online)

Also available at
    Permissions and Reprints

Abstract

Enterococci with special resistance patterns (mainly vancomycin-resistant enterococci) play an important role in everyday clinical practice. Rising resistance rates to linezolid, daptomycin or tigecycline are also increasingly reported. Therapeutically, linezolid and daptomycin are the most important substances mainly in infections due to vancomycin-resistant enterococci. Several systematic meta-analyses of bloodstream infections showed discrepant results in the comparison of mortality of linezolid and daptomycin-treated bacteraemias. The containment of enterococci with special resistance patterns is currently receiving great attention. The key hygienic issue in all recommendations for dealing with multidrug-resistant enterococci can be summarized very simply: current scientific evidence is often inconsistent and studies that have clearly tested a single intervention for efficacy are lacking. The present work gives an insight into the current epidemiology and therapeutic strategies. Furthermore, the recently published German KRINKO recommendations are presented.

Enterokokken mit speziellen Resistenzen spielen im klinischen Alltag eine wichtige Rolle, zumal auch neue Reserveantibiotika zunehmend an Wirksamkeit verlieren. Dieser Beitrag gibt einen Einblick in die aktuelle Epidemiologie und stellt die Optionen zur Eindämmung von Enterokokken mit besonderen Resistenzmechanismen vor. Dazu gehört neben der Umsetzung der kürzlich veröffentlichten KRINKO-Empfehlungen eine effektive medikamentöse Therapie.

Schlüsselwörter

Vancomycin-resistente Enterokokken - Linezolid - Daptomycin - cfr - KRINKO

Key words

vancomycin-resistant enterococci - linezolid - daptomycin - cfr - KRINKO
 

  • Literatur

  • 1 McDermott H, Skally M, O’Rourke J. et al. Vancomycin-Resistant Enterococci (VRE) in The Intensive Care Unit in a Nonoutbreak Setting: Identification of Potential Reservoirs and Epidemiological Associations Between Patient and Environmental VRE. Infect Control Hosp Epidemiol 2018; 39: 40-45 . doi:10.1017/ice.2017.248
    CrossrefPubMedGoogle Scholar
  • 2 Prematunge C, MacDougall C, Johnstone J. et al. VRE and VSE Bacteremia Outcomes in the Era of Effective VRE Therapy: A Systematic Review and Meta-analysis. Infect Control Hosp Epidemiol 2016; 37: 26-35 . doi:10.1017/ice.2015.228
    CrossrefPubMedGoogle Scholar
  • 3 Kramer TS, Remschmidt C, Werner S. et al. The importance of adjusting for enterococcus species when assessing the burden of vancomycin resistance: a cohort study including over 1000 cases of enterococcal bloodstream infections. Antimicrobial resistance and infection control 2018; 7: 133 . doi:10.1186/s13756-018-0419-9419
    CrossrefPubMedGoogle Scholar
  • 4 Bender JK, Cattoir V, Hegstad K. et al. Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: towards a common nomenclature. Drug Resistance Updates 2018; DOI: 10.1016/j.drup.2018.10.002.
    CrossrefPubMedGoogle Scholar
  • 5 KRINKO. Hygienemaßnahmen zur Prävention der Infektion durch Enterokokken mit speziellen Antibiotikaresistenzen. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2018; 61: 1310-1361
    CrossrefPubMedGoogle Scholar
  • 6 Bender JK, Fleige C, Klare I. et al. Detection of a cfr(B) Variant in German Enterococcus faecium Clinical Isolates and the Impact on Linezolid Resistance in Enterococcus spp. PLoS One 2016; 11: e0167042 . doi:10.1371/journal.pone.0167042
    CrossrefPubMedGoogle Scholar
  • 7 Hayden MK, Trenholme GM, Schultz JE. et al. In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate. J Infect Dis 1993; 167: 1224-1227
    CrossrefPubMedGoogle Scholar
  • 8 Fiedler S, Bender JK, Klare I. et al. Tigecycline resistance in clinical isolates of Enterococcus faecium is mediated by an upregulation of plasmid-encoded tetracycline determinants tet(L) and tet(M). J Antimicrob Chemother 2016; 71: 871-881 . doi:10.1093/jac/dkv420
    CrossrefPubMedGoogle Scholar
  • 9 Tasina E, Haidich AB, Kokkali S. et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011; 11: 834-844 . doi:10.1016/S1473-3099(11)70177-3
    CrossrefPubMedGoogle Scholar
  • 10 Bi R, Qin T, Fan W. et al. The emerging problem of linezolid-resistant enterococci. J Glob Antimicrob Resist 2018; 13: 11-19 . doi:S2213-7165(17)30205-9
    CrossrefPubMedGoogle Scholar
  • 11 Lellek H, Franke GC, Ruckert C. et al. Emergence of daptomycin non-susceptibility in colonizing vancomycin-resistant Enterococcus faecium isolates during daptomycin therapy. Int J Med Microbiol 2015; 305: 902-909 . doi:10.1016/j.ijmm.2015.09.005
    CrossrefPubMedGoogle Scholar
  • 12 Balli EP, Venetis CA, Miyakis S. Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia. Antimicrob Agents Chemother 2014; 58: 734-739 . doi:10.1128/AAC.01289-13
    CrossrefPubMedGoogle Scholar
  • 13 Chuang YC, Wang JT, Lin HY. et al. Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis. BMC Infect Dis 2014; 14: 687 . doi:10.1186/s12879-014-0687-9
    CrossrefPubMedGoogle Scholar
  • 14 Whang DW, Miller LG, Partain NM. et al. Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections. Antimicrob Agents Chemother 2013; 57: 5013-5018 . doi:10.1128/AAC.00714-13
    CrossrefPubMedGoogle Scholar
  • 15 Casapao AM, Kullar R, Davis SL. et al. Multicenter study of high-dose daptomycin for treatment of enterococcal infections. Antimicrob Agents Chemother 2013; 57: 4190-4196 . doi:10.1128/AAC.00526-13
    CrossrefPubMedGoogle Scholar
  • 16 Britt NS, Potter EM, Patel N. et al. Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients. Clin Infect Dis 2015; 61: 871-878 . doi:10.1093/cid/civ444
    CrossrefPubMedGoogle Scholar
  • 17 Foolad F, Taylor BD, Shelburne SA. et al. Association of daptomycin dosing regimen and mortality in patients with VRE bacteraemia: a review. J Antimicrob Chemother 2018; 73: 2277-2283 . doi:10.1093/jac/dky072
    CrossrefPubMedGoogle Scholar
  • 18 Smith JR, Barber KE, Raut A. et al. beta-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 2015; 70: 1738-1743 . doi:10.1093/jac/dkv007
    PubMedGoogle Scholar
  • 19 Allen GP, Cha R, Rybak MJ. In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2002; 46: 2606-2612
    CrossrefPubMedGoogle Scholar
  • 20 Klupp EM, Both A, Belmar Campos C. et al. Tedizolid susceptibility in linezolid- and vancomycin-resistant Enterococcus faecium isolates. Eur J Clin Microbiol Infect Dis 2016; 35: 1957-1961 . doi:10.1007/s10096-016-2747-0
    CrossrefPubMedGoogle Scholar
  • 21 Baltch AL, Smith RP, Ritz WJ. et al. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1998; 42: 2564-2568
    CrossrefPubMedGoogle Scholar